Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 1
2014 1
2016 1
2017 1
2018 2
2019 6
2020 6
2021 3
2022 6
2023 4
2024 9
2025 10
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Antonarakis ES, et al. N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3. N Engl J Med. 2014. PMID: 25184630 Free PMC article.
BACKGROUND: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor spli …
BACKGROUND: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide a …
Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, Takahashi H, Urabe F, Mori K, Tashiro K, Iwatani K, Shimomura T, Habuchi T, Kimura T. Yanagisawa T, et al. Prostate. 2025 Feb;85(2):165-174. doi: 10.1002/pros.24813. Epub 2024 Oct 17. Prostate. 2025. PMID: 39417629
Based on the LATITUDE criteria, the comparison among abiraterone, enzalutamide, and apalutamide was exclusively conducted in high-risk patients. ...Our data on differential treatment discontinuation rates, PSA response, and AE profiles can help guide clinical decisi …
Based on the LATITUDE criteria, the comparison among abiraterone, enzalutamide, and apalutamide was exclusively conducted in high-ris …
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Oscroft E, Barker L, Degboe A, Clarke NW. Saad F, et al. Eur Urol Oncol. 2024 Dec;7(6):1394-1402. doi: 10.1016/j.euo.2024.03.006. Epub 2024 Apr 6. Eur Urol Oncol. 2024. PMID: 38582650 Free article. Clinical Trial.
OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of olaparib plus abiraterone versus placebo plus abiraterone. DESIGN, SETTING, AND PARTICIPANTS: A randomised (1:1), double-blind …
OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of …
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Fizazi K, et al. Ann Oncol. 2026 Jan;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Epub 2025 Oct 19. Ann Oncol. 2026. PMID: 41120017 Free article. Clinical Trial.
Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placebo plus abiraterone arms, respectively. ...AE profile was consistent with that of the individual agents. Patients with PTEN-def …
Deaths associated with an AE were reported in 36 (7.2%) and 26 (5.2%) patients in the capivasertib plus abiraterone and placeb …
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, Flohr P, Miranda S, Bertan C, Ferreira A, Crespo M, Rodrigues DN, Gurel B, Nobes J, Crabb S, Malik Z, Ralph C, McGovern U, Hoskin P, Jones RJ, Birtle A, Gale J, Sankey P, Jain S, McLaren D, Chadwick E, Espinasse A, Hall E, de Bono J. Rescigno P, et al. Eur J Cancer. 2024 Jul;205:114103. doi: 10.1016/j.ejca.2024.114103. Epub 2024 May 8. Eur J Cancer. 2024. PMID: 38729054 Free PMC article. Clinical Trial.
BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combin …
BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in met …
Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS database.
Zhang SH, Xu JZ, Zeng N, Xia ZY, Miao LT, Zhang C, Wang SG, Xia QD. Zhang SH, et al. Expert Opin Drug Saf. 2025 Jun 5:1-11. doi: 10.1080/14740338.2025.2496434. Online ahead of print. Expert Opin Drug Saf. 2025. PMID: 40462621
METHODS: Data on AEs for abiraterone acetate and olaparib were extracted from the FDA Adverse Event Reporting System (FAERS) database between April 2011 and April 2024. The reporting odds ratio (ROR) was mainly utilized to analyze AEs and their preferred terms (PTs). RESUL …
METHODS: Data on AEs for abiraterone acetate and olaparib were extracted from the FDA Adverse Event Reporting System (FAERS) database …
Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life-A Systematic Review and Meta-analysis.
Fazekas T, Miszczyk M, Giesen A, Kói T, Zattoni F, Rodriguez-Sanchez L, Yanagisawa T, Matsukawa A, Szarvas T, Kryst P, Rivas JG, Merseburger AS, Santis M, Joniau S, Briganti A, Marra G, Nyirády P, Gandaglia G, Shariat SF, Rajwa P; EAU-YAU Prostate Cancer Working Group. Fazekas T, et al. Eur Urol Focus. 2025 May 21:S2405-4569(25)00118-X. doi: 10.1016/j.euf.2025.05.006. Online ahead of print. Eur Urol Focus. 2025. PMID: 40404535 Free article. Review.
CONCLUSIONS AND CLINICAL IMPLICATIONS: ARPI monotherapy results in overall similar toxicities for ARPI + ADT and ADT alone. The specific AE pattern of each combination can serve as a basis to tailor therapy to each patient's needs and wishes....
CONCLUSIONS AND CLINICAL IMPLICATIONS: ARPI monotherapy results in overall similar toxicities for ARPI + ADT and ADT alone. The specific …
Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q, Ding L, Liu W, Dong S, Zhao T, Yu Y, Guo C, Yao X, Peng B, Yang B. Xie J, et al. Eur Urol Oncol. 2024 Oct;7(5):1088-1096. doi: 10.1016/j.euo.2024.02.005. Epub 2024 Mar 7. Eur Urol Oncol. 2024. PMID: 38458891
Our aim was to compare the efficacy of olaparib + abiraterone versus olaparib monotherapy for patients with DDR-deficient mCRPC progressing after abiraterone. ...CONCLUSIONS: Olaparib + abiraterone resulted in better PFS and OS than olaparib alone for patient …
Our aim was to compare the efficacy of olaparib + abiraterone versus olaparib monotherapy for patients with DDR-deficient mCRPC progr …
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.
Matsubara N, de Bono J, Sweeney C, Chi KN, Olmos D, Sandhu S, Massard C, Garcia J, Chen G, Harris A, Schenkel F, Sane R, Hinton H, Bracarda S, Sternberg CN. Matsubara N, et al. Clin Genitourin Cancer. 2023 Apr;21(2):230-237.e1. doi: 10.1016/j.clgc.2023.01.001. Epub 2023 Jan 7. Clin Genitourin Cancer. 2023. PMID: 36697317 Free article. Clinical Trial.
MATERIALS AND METHODS: In this randomised, double-blind, phase 3 trial, patients with previously untreated asymptomatic or mildly symptomatic mCRPC were randomised 1:1 to receive ipatasertib-abiraterone or placebo-abiraterone (all with prednisone/prednisolone). AEs …
MATERIALS AND METHODS: In this randomised, double-blind, phase 3 trial, patients with previously untreated asymptomatic or mildly symptomati …
Chemistry and bioactivities of natural steroidal alkaloids.
Xiang ML, Hu BY, Qi ZH, Wang XN, Xie TZ, Wang ZJ, Ma DY, Zeng Q, Luo XD. Xiang ML, et al. Nat Prod Bioprospect. 2022 Jun 15;12(1):23. doi: 10.1007/s13659-022-00345-0. Nat Prod Bioprospect. 2022. PMID: 35701630 Free PMC article. Review.
They have demonstrated a wide range of biological activities, and some of them have even been developed as therapeutic drugs, such as abiraterone acetate (Zytiga()), a blockbuster drug, which has been used for the treatment of prostate cancer. ...
They have demonstrated a wide range of biological activities, and some of them have even been developed as therapeutic drugs, such as abi …
46 results